Medical professional administering a vaccine into a patient's arm

Who would first benefit from a Covid-19 vaccine?

It’s proven a challenging year so far in 2020, particularly as a result of Covid-19, so news that a potential vaccine candidate has shown promising results has been greeted with a significant sense of optimism. But, should the vaccine meet the remaining criteria and be approved for use, who would benefit first from it?

Well, at least here in the UK, the biggest risk factor for contracting and developing severe and potentially fatal Covid-19 cases has been identified as within the care home sector.

Particularly among older care home residents, the risk of serious ill health as a result of Covid-19 is significantly heightened.

As such, it is expected that elderly care home residents and the staff looking after them would be top of any preliminary priority list for a vaccine.

This would be closely followed by health workers, such as hospital staff.

Within the wider population, people are likely to be ranked by age – with those who are identified as healthy, with minimal risk and under the age of 50 towards the bottom of the list. This is due to a lower risk of serious Covid-19 infection than those over the age of 50 or with existing health complications, two severely at-risk groups who have accounted for a significant proportion of the deaths from the virus in the UK to date.

Initial optimism has been followed by suggestions that, should all remaining processes go smoothly, the first vaccinations could take place even before Christmas. There remains a number of notable hurdles to overcome though, particularly logistically when it comes to vaccinating the wider population.

It is expected the vaccine will be delivered through care homes, GPs and pharmacists, as well as the establishing of a network of “go-to” vaccination centres set up in sports halls and such facilities.

However, transportation and storage of the vaccine could prove challenging initially.

With requirements to be stored at minus 80C, the vaccine needs to remain in a process called cold chain storage – whereby it remains in a temperature-controlled supply chain.

An unbroken cold chain refers to an uninterrupted series of refrigerated production, storage and distribution activities to guarantee the vaccine is kept continually at the desired low-temperature range and it remains as effective as intended.

The UK has some cold chain capabilities, with NHS sites well-equipped, but at present it will remain out of reach of many local GP surgeries and makeshift vaccination centres without notable investment and financial support from Government.

NHE Jan.Feb 21

NHE Jan/Feb 21

Creating a net zero NHS

NHE’s Jan/Feb 2021 edition focuses on the role of pharma working alongside the NHS, how we are working to digitise the health service and the ways in which the NHS can be involved in addressing the climate emergency.


View all videos
BMC Whitepaper


How well do the NHS understand digital potential?

Recently we have been gathering primary data direct from those within the NHS on modernising NHS technology and the challenges faced around resource, training and service management.

Download the full whitepaper and read the full findings in our exclusive report to learn more.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all